A tech giant with low valuation, high growth, and high dividend yield—its interim report performance exceeded expectations. Is it highly worth watching?

Series XI: A global giant with high dividend payout; its interim report performance is exceptionally stable, and its valuation sits in a historically undervalued zone—Feng Liu of High-Flyer Asset Management is continuously increasing positions! Series XII: A tech giant whose earnings are approaching an inflection point! Its valuation remains at a historical low—High-Flyer Asset Management holds a heavy position! Series XI: The strongest and most undervalued 'hidden champion' in the tech sector! (Interpretation of Hikvision’s 2024 Earnings Preview) Series XII: A tech-sector giant—the strongest and most undervalued 'hidden champion'—is it worth watching? (Interpretation of Hikvision’s 2024 Annual Report) Series XIII: A global giant with high dividend payout; its interim report performance continues robust growth, and its valuation remains at a historical low! (Interpretation of Hikvision’s 2025 Semi-Annual Report) Series XIV: A global giant with high dividend payout; its third-quarter report performance continues robust growth, and its valuation remains at a historical low! (Interpretation of Hikvision’s 2025 Third-Quarter Report) Series XV: This tech giant’s earnings have turned around from difficulty—low valuation, high dividend payout—is it highly worth watching? (Interpretation of Hikvision’s 2025 Annual Report) On July 24, 2026, Hikvision released its 2026 semi-annual operating results: revenue reached RMB 46.82 billion, up 11.97% year-on-year; net profit totaled RMB 7.896 billion, up 39.57% year-on-year. Q2 revenue amounted to RMB 26.107 billion, up 12.11% year-on-year; net profit reached RMB 5.115 billion, up 41.34% year-on-year. The company’s H1 2026 earnings continued to exceed expectations. Since Q1 2025, performance has steadily improved and accelerated: Q1 2025 net profit grew 6.41%, Q2 grew 14.94%, Q3 grew 20.31%, Q4 grew 26.01%, Q1 2026 grew 36.42%, and Q2 2026 grew 41.34%. This year’s H1 net profit of RMB 7.896 billion set a new record—indicating that net profit had stagnated at low levels for four years, and 2026 is poised to achieve a new high. In the investor briefing on July 25, management expressed strong confidence, stating: 'We expect 2026 revenue to surpass RMB 100 billion and profits to reach a new all-time high.' However, although the company’s profits hit a new high, operating cash flow stood at RMB 3.23 billion—down sharply by 39.52% year-on-year from RMB 5.34 billion last year. Why? The primary reason is inventory buildup: H1 2026 inventory totaled RMB 29.5 billion, up RMB 10.4 billion (54.5%) year-on-year from RMB 19.1 billion. This substantial inventory increase stems mainly from preparations against broad-based price hikes and shortages of electronic components. Meanwhile, accounts receivable showed marked improvement in H1 2026: they declined to RMB 27.8 billion from RMB 34.8 billion year-on-year—a 20% drop—even as revenue rose significantly. As a result, days sales outstanding (DSO) fell sharply to 110 days from 156 days year-on-year—a reduction of 46 days—indicating substantially enhanced pricing power over downstream customers. Similarly, contract liabilities surged: H1 2026 contract liabilities reached RMB 4.92 billion, up 45.6% year-on-year from RMB 3.38 billion; Q1 2026 contract liabilities stood at RMB 4.67 billion, up 42.8% year-on-year from RMB 3.27 billion. This sharp YoY growth in contract liabilities reflects strong product competitiveness and high prepayment enthusiasm among downstream distributor customers—providing a 'reservoir' for next quarter’s revenue growth.

Forward-looking summary of overall pharmaceutical sector performance + CXO sector outlook

Pharmaceutical Sector Performance Outlook for Q2 2026: New Molecular Modalities Drive Strong CXO Growth; Peptides and ADCs Lead the Way Summary · CXO sector sentiment is rebounding; rising capacity utilization and new-molecule-related business are driving improvements in net margin and ROE, resulting in pronounced earnings elasticity. · Peptide CDMO is entering an explosive growth phase, with the global market expected to exceed USD 160 billion by 2030; WuXi AppTec holds a 25% global GLP-1 market share, while Asymchem accelerates capacity expansion. · Large-molecule CDMO shows a 'strong get stronger' pattern: WuXi Biologics hosts over 200 bispecific antibody projects; WuXi XDC holds >25% global ADC market share—the highest globally. · Q2 2026 Performance Outlook: Medicilon’s profit growth is expected to reach 1,700–2,300% (due to base-effect); Sciex Tech and Biotheus are projected to deliver ~50% profit growth. · China’s CDMO capital expenditure far exceeds India’s: WuXi AppTec invests ~USD 1 billion annually; starting in 2026, it enters a new round of accelerated capacity expansion to capture greater global market share. · Consumer healthcare has bottomed out and stabilized; the TCM sector trades at relatively low valuations and offers high dividend yields; medical device exports and small-molecule nucleic acid therapeutics—expanding indications into chronic diseases—are projected to exceed USD 30 billion globally by 2030; WuXi AppTec and Asymchem already possess commercial-scale production advantages. Q&A Please summarize the overall pharmaceutical sector performance expectations for Q2 2026, and specifically analyze growth trends and divergence characteristics across key sub-sectors—including innovative drugs, CXO, medical devices, traditional Chinese medicine (TCM), and consumer healthcare. Overall, the pharmaceutical sector is expected to maintain relatively steady growth in Q2 2026, though sub-sector performance will diverge significantly: · Innovative Drugs: Revenue growth will be notably faster; certain companies’ drug sales revenue growth is particularly strong—for example, Kelun-Biotech and Conova. This reflects large R&D investments by many biotechs, which temporarily pressure profitability—making revenue growth a more reliable indicator of underlying momentum. · CXO: Both revenue and profit growth are outstanding. The sector is recovering from prior lows, with rising capacity utilization and contributions from new molecular modalities jointly boosting net margins and ROE—delivering meaningful earnings elasticity. · Medical Devices: Company-level performance varies widely, but the sector overall remains stable. Export-oriented firms show relatively stronger growth. · Traditional Chinese Medicine (TCM): Overall growth is modest, with only select companies sustaining double-digit growth. After several years of adjustment, the sector now trades at relatively low valuations, and some stocks offer high dividend yields. Future earnings inflection points—and recent policy developments regarding essential medicines—warrant close monitoring. · Consumer Healthcare: Q2 shows signs of bottoming out and stabilizing, maintaining relative steadiness. Some companies approach double-digit growth, broadly falling within the single- to low-double-digit range. Based on the Q2 2026 performance outlook, which companies exhibit notably strong earnings and revenue growth expectations? According to the Q2 2026 outlook, growth expectations break down as follows: · Earnings Growth: Companies exceeding 50% YoY profit growth are concentrated in the CXO space—including Medicilon (base-effect driven, projected profit growth of 1,700–2,300%), Biotheus (70–90%), and Sciex Tech (50–70%). Companies with 30–50% profit growth include WuXi AppTec (median ~30%) and others near 30%, such as Tigermed. Those with 20–30% profit growth are also predominantly CXO and select medical device firms—including Asymchem, BioProtein Sciences, United Imaging Healthcare, Huitai Medical, and New Industries. · Revenue Growth: Innovative drug companies lead here. Excluding BD upfront payments and milestone revenues—and focusing solely on drug sales revenue—Kelun-Biotech and Conova are projected to post rapid year-on-year growth.

Chemours releases second quarter 2026 results

Aug 6, 2026

Chemours reported flat net sales of USD 1.6 billion for Q2 2026, though free cash flow surged 128% to USD 114 million. The company maintained its full-year outlook despite a net loss and volume declines in Titanium Technologies.

European Coatings

2026-07-27

US Environmental Groups Urge EPA to Reject New PFAS for Datacenter Cooling

2026-07-28

Coalition Urges EPA to Reject Chemours PFAS Fluid for Data Center Cooling

2026-07-31

US Groups Tell EPA to Reject Fast-Tracked Data Center PFAS, Warn It Would Pollute Nearby Areas

2026-08-06

Chemours releases second quarter 2026 results

2026-08-10

The Chemours Company Launches Opteon ZE and Opteon 515B Refrigerants for Chiller Applications